Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.910 -0.090 (-4.50%)
Streaming Delayed Price Updated: 12:34 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 606,072
Open 1.950
Bid (Size) 1.900 (6,700)
Ask (Size) 1.910 (2,900)
Prev. Close 2.000
Today's Range 1.880 - 1.976
52wk Range 0.9573 - 3.535
Shares Outstanding 60,705,391
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
From Caribou Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
+20.1%
+20.1%
1 Month
-16.6%
-16.6%
3 Month
+17.9%
+17.9%
6 Month
+4.9%
+4.9%
1 Year
+73.6%
+73.6%

More News

Read More
News headline image
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments ↗
Via Stocktwits
News headline image
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
From Equity Insider
Via GlobeNewswire
News headline image
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today? ↗
Via Benzinga
News headline image
Gapping stocks in Monday's session ↗
Via Chartmill
News headline image
Discover the top movers in Monday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
News headline image
Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
From Caribou Biosciences, Inc.
Via GlobeNewswire
News headline image
Caribou Biosciences Inc (NASDAQ:CRBU) Posts Mixed Q2 2025 Earnings with Revenue Beat but Wider Loss ↗
Via Chartmill

Frequently Asked Questions

Is Caribou Biosciences, Inc. - Common Stock publicly traded?
Yes, Caribou Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Caribou Biosciences, Inc. - Common Stock trade on?
Caribou Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Caribou Biosciences, Inc. - Common Stock?
The ticker symbol for Caribou Biosciences, Inc. - Common Stock is CRBU on the Nasdaq Stock Market
What is the current price of Caribou Biosciences, Inc. - Common Stock?
The current price of Caribou Biosciences, Inc. - Common Stock is 1.910
When was Caribou Biosciences, Inc. - Common Stock last traded?
The last trade of Caribou Biosciences, Inc. - Common Stock was at 05/21/26 12:34 PM ET
What is the market capitalization of Caribou Biosciences, Inc. - Common Stock?
The market capitalization of Caribou Biosciences, Inc. - Common Stock is 115.95M
How many shares of Caribou Biosciences, Inc. - Common Stock are outstanding?
Caribou Biosciences, Inc. - Common Stock has 116M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.